

YHP1701

YHP1701: A combination drug for co-existing hypertension and hyperlipidemia. YHP1701 is a double-layer combination IMD for the simultaneous treatment of hypertension and hyperlipidemia. This is the first of its kind under development in Korea. In comparison to existing combinations, it is expected to have increased efficacy but with reduced adverse effects. Phase III clinical trials has completed on idiopathic hypertension patients suffering dyslipidemia to confirm its superiority to treatment with individual agents.